PBAC to investigate survival benefit of Yervoy for melanoma

In an interview on the ABC’s Four Corners last night, Pharmaceutical Benefits Advisory Committee (PBAC) chair Dr Suzanne Hill said the government’s decision to seek such data was the result of the committee having to increasingly make decisions to list drugs “on the basis of smaller clinical trials”.

When announcing the funding of the drug last month, Health Minister Tanya Plibersek said it would save patients more than $110,000 a year.

The ABC reported that despite costing the government $430 million over the next four years, there had been no attempt to “systematically follow up with patients to see if the drugs do indeed deliver the benefits claimed by pharmaceutical companies”.

"For Yervoy, what we want to look at is who gets prescribed it, what happens to them, how long do they get treatment for, how is the treatment with